DEME takes delivery of its second new wind turbine installation vessel Norse Energi DEME has taken delivery of its second new wind turbine installation vessel, Norse Energi, today at the CIMC Raffles Shipyard. As the sister vessel of the recently delivered Norse Wind, Norse Energi is purpose‑built to install the next generation of large-scale offshore wind turbines. Featuring advanced technology, exceptional lifting and loading capabilities, and sustainable design features, both vessels will help reinforce DEME’s position at the forefront of offshore wind installation. Attachments ...
DEME neemt tweede nieuwe installatieschip voor windturbines Norse Energi in ontvangst DEME heeft vandaag op de CIMC Raffles-scheepswerf zijn tweede nieuwe installatieschip voor windturbines, Norse Energi, in ontvangst genomen. Als zusterschip van het recent opgeleverde Norse Wind is Norse Energi speciaal gebouwd om de volgende generatie grootschalige offshore windturbines te installeren. Met geavanceerde technologie, uitzonderlijke hijs- en laadcapaciteiten en een duurzaam ontwerp zullen beide schepen DEME’s positie als koploper in installatie van offshorewind verder verstevigen. Bijla...
A director at Argen X SE sold after exercising options/sold 3,625 shares at 695.710EUR and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over t...
argenx announced that the FDA has accepted for priority review a sBLA for Vyvgart IV for the treatment of adults with acetylcholine receptor antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG), with a PDUFA target action date of 10 May 2026. The sBLA acceptance and priority review for Vyvgart in seronegative gMG brings argenx a step closer to its aim of having the broadest possible label in this setting. argenx estimates the commercial opportunity for seronegative gMG could add 1...
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG January 13, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review a supplemental Biologics License Application (sBLA) for VYVGART® (IV: efgartigimod alfa-fcab) for the treatment of adults with acetylcholine recepto...
argenx outlined its strategic priorities for 2026 and shared preliminary Vyvgart sales numbers coming in at $ 4.15b for FY25, more or less in line with CSS of $ 4.13b. Looking ahead, 2026 is set to be a catalyst rich year with 4 registrational readouts and we note that argenx provided more specific timeline guidance for each trial, while the earlier stage pipeline progresses with multiple new additions, and a biotech collaboration. We continue to see upside for the stock in 2026 and maintain our...
We hosted our 29th ODDO BHF Forum in Lyon on 8 and 9 January 2026. In total, 220 companies presented over the two days. In the following note, we provide some initial feedback from the companies on Day 2, in addition to Day 1 feedback (Link to Day 1 feedback). Key positive companies were Corbion, DEME, Elia Group, Knorr Bremse, Sulzer, Séché Environnement, Fraport, Vallourec and TUI. More cautious companies were Arkema, Fastned, INWIT, Manitou, Roche Bobois, Téléperformance, and Colonial SFL. T...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.